Dextrallorphan

Dextrallorphan
Clinical data
Routes of
administration		 Oral
ATC code none
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 5822-43-5
PubChem (CID) 5748237
ChemSpider 2339009
Chemical and physical data
Formula C19H25NO
Molar mass 283.41 g/mol
3D model (Jmol) Interactive image

Dextrallorphan (DXA) is an opioid derivative chemical of the morphinan class that is used in scientific research. It acts as a σ1 receptor agonist and NMDA receptor antagonist.[1][2][3][4] It has no significant affinity for the σ2, μ-opioid, or δ-opioid receptor, or for the serotonin or norepinephrine transporter.[2][5] As an NMDA receptor antagonist, in vivo, it is approximately twice as potent as dextromethorphan, and five-fold less potent than dextrorphan.[3]

Uses in Scientific Research

Masking of sigma-1 receptor

Dextrallorphan is often used in research to block σ1 receptor sites so that σ2 receptor sites (which have not been cloned yet) can be studied.[6][7][8] It was hypothesized that both of these sigma (σ) receptors were opioid receptors, due to their affinity for psychoactive drugs. However, it is now understood that they are non-opioid receptors that bind to certain psychoactive drugs, like dextrallorphan.[9] One example of dextrallorphan being used to mask σ1 receptor sites was seen in a study on the localization of the σ2 receptor in detergent-resistant lipid raft domains.[6] It has also been used to mask σ1 receptor sites so that σ2 receptor binding characteristics in the rat liver could be determined, by labeling σ2 receptor sites with [3H]l,3-di-o-tolylguanidine (DTG) in the presence of 1 μM dextrallorphan solution.[8]

Animal Studies

Dextrallorphan was used in Spraque-Dawley rats to study cerebellar Purkinje neurons electrophysical responses to the drug when it was applied iontophoretically as a sigma (σ) receptor ligand. Dextrallorphan increased the firing rate by 14%, suggesting that sigma (σ) ligands (like dextrallorphan) alter the spontaneous firing of Purkinje neurons and cause motor effects.[10]

In another study, dextrallorphan, along with other opioid derivatives, was found to be a potent inhibitor of etorphine-inaccessible (EI) sites in the guinea-pig brain. Dextrallorphan was of the top three most potent opioid inhibitors of those studied, with a concentration of 67 nM required to show 50% inhibition.[1]

History

In 1955, dextrallorphan has been used to study inhibition of cholinesterase's and to look at the relationship between analgetics and acetylcholine metabolism.[11] It was found that dextrallorphan inhibits 25% of bovine erythrocyte cholinesterase at a dose of 10−3 mole/liter, which corresponds to a concentration of up to 0.2 mg/kg in dog intestine. However, at this dose the drug showed no effect on the gut tone. Dextrallorphan was classified as a potent inhibitor of the intestinal and red blood cell cholinesterase based on the concentration of the drug needed to inhibit these enzymes in the cholinesterase preparations from the animals systems utilized. Simultaneously, dextrallorphan showed no analgesia and no change in intestinal tone. With these results dextrallorphan helped proved that there is no correlation between the inhibition of cholinesterase systems and analgetic or intestinal effects.[12]

In 1979, dextrallorphan was found to have a half maximal inhibitory concentration (IC50) for binding to the pituitary and brain receptor of 10,000 ± 1000 nM and 10,000 ± 1500 nM, respectively. While its stereoisomer, levellorphan, had a 10,000 times more potent dose, thus proving that binding to these receptors is stereospecific.[13]

See also

References

  1. 1 2 Su, T. P. (Nov 1982). "Evidence for Sigma Opioid Receptor: Binding of [3H]SKF-10047 to Etorphine-Inaccessible Sites in Guinea-Pig Brain" (pdf). The Journal of Pharmacology and Experimental Therapeutics. 223 (2): 284–290. PMID 6290634.
  2. 1 2 Codd, E. E.; Shank, R. P.; Schupsky, J. J.; Raffa, R. B. (Sep 1995). "Serotonin and Norepinephrine Uptake Inhibiting Activity of Centrally Acting Analgesics: Structural Determinants and Role in Antinociception" (pdf). The Journal of Pharmacology and Experimental Therapeutics. 274 (3): 1263–1270. PMID 7562497.
  3. 1 2 Shukla, V. K.; Lemaire, S. (Jan 1997). "N-Methyl-D-Aspartate Antagonist Activity of Alpha- and Beta-Sulfallorphans" (pdf). The Journal of Pharmacology and Experimental Therapeutics. 280 (1): 357–365. PMID 8996216.
  4. ↑ Shannon, H. E. (Apr 1983). "Pharmacological Evaluation of N-Allynormetazocine (SKF 10,047) on the Basis of its Discriminative Stimulus Properties in the Rat". The Journal of Pharmacology and Experimental Therapeutics. 225 (1): 144–152. PMID 6834266.
  5. ↑ He, X. S.; Bowen, W. D.; Lee, K. S.; Williams, W.; Weinberger, D. R.; de Costa, B. R. (Mar 1993). "Synthesis and Binding Characteristics of Potential SPECT Imaging Agents for Sigma-1 and Sigma-2 Binding Sites". Journal of Medicinal Chemistry. 36 (5): 566–571. doi:10.1021/jm00057a006. PMID 8496936.
  6. 1 2 Gebreselassie, D.; Bowen, W. D. (June 2004). "Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes" (pdf). European Journal of Pharmacology. 493 (1-3): 19–28. doi:10.1016/j.ejphar.2004.04.005. PMID 15189760.
  7. ↑ Maeda, D. Y.; Williams, W.; Bowen, W. D.; Coop, A. (Jan 2000). "SA sigma-1 receptor selective analogue of BD1008. a potential substitute for (+)-opioids in sigma receptor binding assays" (pdf). Bioorganic & Medicinal Chemistry Letters. 10 (1): 17–18. doi:10.1016/s0960-894x(99)00590-9. PMID 10636233.
  8. 1 2 Torrence-Campbell, C.; Bowen, W. D. (May 1996). "Differential solubilization of rat liver sigma-1 and sigma- 2 receptors: retention of sigma- 2 sites in particulate fractions" (pdf). European Journal of Pharmacology. 304 (1-3): 201–210. doi:10.1016/0014-2999(96)00109-4. PMID 8813603.
  9. ↑ Hayashi, T.; Su, T. (Oct 2005). "The Sigma Receptor: Evolution of the Concept in Neuropsychopharmacology". Current Neuropharmacology. 3 (4): 267–280. doi:10.2174/157015905774322516. PMC 2268997Freely accessible. PMID 18369400.
  10. ↑ Martin, W. J.; De Costa, B. R.; Walker, J. M. (1994). "Effects of σ ligands on rat cerebellar purkinje neuron firing: An iontophoretic study" (pdf). Brain Research Bulletin. 35 (4): 303–309. doi:10.1016/0361-9230(94)90106-6.
  11. ↑ Eikenburg, D. C.; Stickney, J. L. (1979). "Anti-Cholinesterase Activity of 1-α-acetylmethadol: Relationship of Bradycardia" (pdf). General Pharmacology. 10 (3): 195–200. doi:10.1016/0306-3623(79)90089-2. PMID 467958.
  12. ↑ Young, D. C.; Vander Ploeg, A.; Featherstone, R. M.; Gross, E. G. (May 1955). "The Interrelationships Among the Central, Peripheral and Anticholinesterase Effects of Some Morphinan Derivatives" (pdf). The Journal of Pharmacology and Experimental Therapeutics. 114 (2): 33–37. PMID 14392568.
  13. ↑ Simantov, R.; Snyder, S. H. (Dec 1976). "Opiate receptor binding in the pituitary gland" (pdf). Brain Research. 124 (1): 178–184. doi:10.1016/0006-8993(77)90877-0. PMID 191146.
This article is issued from Wikipedia - version of the 8/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.